ERRATUM



Erratum note: Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China

Xin Guan^{1,2}, Luying Wang^{1,2}, Yang Cao^{1,2}, Fenghao Shi^{1,2}, He Xu^{1,2}, Jie Ding³, Meiyu Wu³, Hongchao Li^{1,2,*}

¹School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China ²Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China ³Sumitomo Pharma (Suzhou) Co., Ltd., Shanghai 200025, China

Erratum to: "Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China (https://doi.org/10.54844/hd.2023.0362).

ERRATUM REASON

Due to the author's lack of careful proofreading, this article was accidentally missing the "Table 6 base case results". In the last paragraph of *Costs of Model Input* section, the "Table 4" should be written as "Table 5" (*A summary of cost*

inputs used in the model is showed in Table 5). In the Base case analysis of Results section, the "Table 5" should be written as "Table 6" (*Table 6 shows the detailed results of the base case analysis*). In the results section of the abstract, the "CNY 173,575" should be written as "CNY 173,757" (*ziprasidone generated 4.28 QALYs with cost of CNY 173,757*).

The authors and editors apologize for this error and state that this does not change the scientific conclusions of the article in any way and does not involve any academic or ethical issues.

Table 6: Base case results					
	Costs (¥)	Incremental costs (¥)	QALY	Incremental QALYs	ICER
Ziprasidone	173,757		4.28		
Blonanserin	167,011	-6,746	4.30	0.02	dominant

QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratio.

*Corresponding Author:

Hongchao Li, E-mail: lihongchao@cpu.edu.cn; https://orcid.org/0000-0001-5151-9724

Received: 20 November 2023; Revised: 22 November 2023; Accepted: 23 November 2023; Published: 24 November 2023

https://doi.org/10.54844/hd.2023.0498

² This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which allows others to copy and redistribute the material in any medium or format non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.